论文部分内容阅读
作者对初免百日咳无细胞菌苗DTP(DTaP)或百日咳全细胞菌苗DTP(DTwP)的儿童15～21月龄时加强接种重组DTaP的安全性和免疫原性进行比较,并对6月龄儿童完成第3剂初免DTaP或DTwP约1年后血清抗体浓度的持久性作了评价。 350名15～21月龄儿童加强接种重组DTaP,其中173名初免用DTaP,177名用DTwP。DTaP 0.5ml含25絮状反应单位(Lf)白喉类毒素(DT)、10Lf破伤风类毒素(TT)、5μg重组百日咳毒素、2.5μg丝状血凝素(FHA)、2.5μg69kDa外膜蛋白和0.05mg硫柳汞。菌苗以1mg氢氧化铝吸附
The authors compared the safety and immunogenicity of vaccinated DTaP boosted at 15 to 21 months of age in children who had initially immunized with B. pertussis DTP (DTaP) or B. pertussis DTP (DTwP) The persistence of serum antibody concentrations after completion of the first dose of DTaP or DTwP at the third dose was assessed after one year. 350 children 15 to 21 months of age to strengthen the vaccination of recombinant DTaP, of which 173 patients with DTaP prime, 177 with DTwP. DTaP 0.5 ml containing 25 flocculent reaction units (Lf) diphtheria toxoid (DT), 10 Lf tetanus toxoid (TT), 5 μg recombinant pertussis toxin, 2.5 μg fibrinogen (FHA), 2.5 μg 69 kDa outer membrane protein and 0.05mg thimerosal. Vaccine was adsorbed with 1 mg aluminum hydroxide